This story was originally published on July 16.
Thermo Fisher Scientific said today after the markets closed that it has completed its previously announced $260 million acquisition of Fermentas.
Thermo Fisher first announced its intent to acquire Fermentas in May. The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR (PCR Insider, 5/27/10).
Fermentas, which is headquartered in Burlington, Ontario, and has principal operations in Vilnius, Lithuania, also provides a broad range of molecular and cellular biology research products, including reagents for nucleic acid and protein purification, restriction and modifying enzymes, molecular weight markers, and other research and diagnostic tools.
Fermentas has approximately 500 employees and had full-year revenues of approximately C$57 million in 2009 (approximately $55 million). The company will be integrated into Thermo Fisher’s Analytical Technologies segment.
In a statement, Thermo said that Fermentas’ "broad range of high-quality molecular and cellular biology research tools, including reagents, enzymes, and kits" will help Thermo to offer a "complete workflow for genomics research while building on its platform of PCR and qPCR tools and resources."